New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...

Dexcom announces the FDA approval of its over-the-counter glucose monitor, which will provide access to new medical resources for those lacking insurance. For those diagnosed with Type 2 Diabetes, a ...

March 24--Shares of DexCom gained more than 8 percent Friday after Medicare issued a favorable ruling for reimbursing use of continuous glucose monitors, made by the San Diego-based company. DexCom ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...